We performed a longitudinal analysis of serum samples in 2 CLL patients (P16 and P46) before and after therapy, which confirmed the predictive value of NGAL levels in CLL patients in remission. The gene discussed is LCN2; the disease is B-cell chronic lymphocytic leukemia.